NASDAQ:SNNA - Sienna Biopharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.96 +0.45 (+3.10 %)
(As of 05/22/2018 02:00 AM ET)
Previous Close$14.51
Today's Range$14.37 - $15.10
52-Week Range$13.37 - $29.25
Volume67,100 shs
Average Volume96,548 shs
Market Capitalization$300.83 million
P/E Ratio-2.88
Dividend YieldN/A
BetaN/A

About Sienna Biopharmaceuticals (NASDAQ:SNNA)

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.

Receive SNNA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNNA
CUSIPN/A
Phone818-629-2256

Debt

Debt-to-Equity RatioN/A
Current Ratio6.84
Quick Ratio6.84

Price-To-Earnings

Trailing P/E Ratio-2.88
Forward P/E Ratio-5.14
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.44 per share
Price / Book3.37

Profitability

EPS (Most Recent Fiscal Year)($5.19)
Net Income$-50,540,000.00
Net MarginsN/A
Return on Equity-110.53%
Return on Assets-45.87%

Miscellaneous

Employees47
Outstanding Shares20,730,000

Sienna Biopharmaceuticals (NASDAQ:SNNA) Frequently Asked Questions

What is Sienna Biopharmaceuticals' stock symbol?

Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA."

How were Sienna Biopharmaceuticals' earnings last quarter?

Sienna Biopharmaceuticals (NASDAQ:SNNA) issued its quarterly earnings results on Monday, May, 14th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.15. View Sienna Biopharmaceuticals' Earnings History.

What price target have analysts set for SNNA?

4 Wall Street analysts have issued 1 year target prices for Sienna Biopharmaceuticals' shares. Their predictions range from $21.00 to $50.00. On average, they expect Sienna Biopharmaceuticals' stock price to reach $32.25 in the next year. View Analyst Ratings for Sienna Biopharmaceuticals.

Who are some of Sienna Biopharmaceuticals' key competitors?

Who are Sienna Biopharmaceuticals' key executives?

Sienna Biopharmaceuticals' management team includes the folowing people:
  • Dr. Frederick C. Beddingfield III, Chief Exec. Officer and Pres (Age 53)
  • Dr. Todd Harris, Head of Corp. Devel. & Director (Age 39)
  • Mr. John W. Smither, Chief Financial Officer (Age 65)
  • Mr. Majed Kheir, VP of Operations (Age 40)
  • Dr. Silvio Traversa BSc Ph.D., Chief Scientific Officer (Age 48)

When did Sienna Biopharmaceuticals IPO?

(SNNA) raised $64 million in an initial public offering (IPO) on Thursday, July 27th 2017. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets acted as the underwriters for the IPO.

Has Sienna Biopharmaceuticals been receiving favorable news coverage?

Headlines about SNNA stock have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sienna Biopharmaceuticals earned a media sentiment score of 0.00 on Accern's scale. They also gave media headlines about the company an impact score of 47.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Sienna Biopharmaceuticals' major shareholders?

Sienna Biopharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.41%), Victory Capital Management Inc. (2.27%), IFP Advisors Inc (0.87%), Northern Trust Corp (0.61%), Cohen Capital Management Inc. (0.55%) and Tiverton Asset Management LLC (0.27%). Company insiders that own Sienna Biopharmaceuticals stock include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson, Robert J More, Timothy K Andrews and Todd Harris. View Institutional Ownership Trends for Sienna Biopharmaceuticals.

Which institutional investors are selling Sienna Biopharmaceuticals stock?

SNNA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. Company insiders that have sold Sienna Biopharmaceuticals company stock in the last year include Robert J More and Todd Harris. View Insider Buying and Selling for Sienna Biopharmaceuticals.

Which institutional investors are buying Sienna Biopharmaceuticals stock?

SNNA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., IFP Advisors Inc, Cohen Capital Management Inc., Northern Trust Corp, Tiverton Asset Management LLC, Schwab Charles Investment Management Inc., Crestwood Advisors Group LLC and Meadow Creek Investment Management LLC. Company insiders that have bought Sienna Biopharmaceuticals stock in the last two years include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson and Timothy K Andrews. View Insider Buying and Selling for Sienna Biopharmaceuticals.

How do I buy shares of Sienna Biopharmaceuticals?

Shares of SNNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sienna Biopharmaceuticals' stock price today?

One share of SNNA stock can currently be purchased for approximately $14.96.

How big of a company is Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals has a market capitalization of $300.83 million. The company earns $-50,540,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis. Sienna Biopharmaceuticals employs 47 workers across the globe.

How can I contact Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected]


MarketBeat Community Rating for Sienna Biopharmaceuticals (SNNA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  155
MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote "Outperform" if you believe SNNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sienna Biopharmaceuticals (NASDAQ:SNNA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Sienna Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $32.25, suggesting that the stock has a possible upside of 115.57%. The high price target for SNNA is $50.00 and the low price target for SNNA is $21.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.753.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.25$32.25$32.25$36.00
Price Target Upside: 115.57% upside57.09% upside57.09% upside85.76% upside

Sienna Biopharmaceuticals (NASDAQ:SNNA) Consensus Price Target History

Price Target History for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Sienna Biopharmaceuticals (NASDAQ:SNNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2017GuggenheimInitiated CoverageNeutral ➝ Neutral$21.00LowView Rating Details
8/21/2017CowenInitiated CoverageOutperform$50.00HighView Rating Details
8/21/2017JPMorgan ChaseInitiated CoverageOverweight ➝ Overweight$28.00HighView Rating Details
8/21/2017BMO Capital MarketsInitiated CoverageOutperform$30.00HighView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Sienna Biopharmaceuticals (NASDAQ:SNNA) Earnings History and Estimates Chart

Earnings by Quarter for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Sienna Biopharmaceuticals (NASDAQ:SNNA) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.91 EPS
Next Year EPS Consensus Estimate: $-2.84 EPS

Sienna Biopharmaceuticals (NASDAQ SNNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018Q1 2018($0.6970)($0.8460)ViewN/AView Earnings Details
3/15/2018Q4 2017($0.56)ViewN/AView Earnings Details
11/9/2017Q3 2017($1.12)ViewN/AView Earnings Details
9/7/2017Q2 2017($0.68)($6.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sienna Biopharmaceuticals (NASDAQ:SNNA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sienna Biopharmaceuticals (NASDAQ SNNA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 27.00%
Institutional Ownership Percentage: 47.85%
Insider Trading History for Sienna Biopharmaceuticals (NASDAQ:SNNA)
Institutional Ownership by Quarter for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Sienna Biopharmaceuticals (NASDAQ SNNA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/30/2018Todd HarrisInsiderSell100$20.00$2,000.00View SEC Filing  
4/25/2018Todd HarrisInsiderSell975$20.00$19,500.00View SEC Filing  
4/18/2018Todd HarrisInsiderSell18,011$20.08$361,660.88View SEC Filing  
4/9/2018Todd HarrisInsiderSell8,210$20.00$164,200.00View SEC Filing  
3/29/2018Robert J MoreDirectorSell24,429$18.80$459,265.20View SEC Filing  
3/19/2018Todd HarrisInsiderSell5,876$20.00$117,520.00View SEC Filing  
3/9/2018Todd HarrisInsiderSell20,672$20.03$414,060.16View SEC Filing  
9/18/2017Dennis M FentonDirectorBuy1,250$22.96$28,700.001,250View SEC Filing  
8/1/2017Keith R LeonardDirectorBuy16,700$15.00$250,500.00View SEC Filing  
8/1/2017Paul F LizzulInsiderBuy10,000$15.00$150,000.0094,634View SEC Filing  
8/1/2017Richard D PetersonCFOBuy7,000$15.00$105,000.007,000View SEC Filing  
8/1/2017Timothy K AndrewsGeneral CounselBuy15,000$15.00$225,000.0051,737View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sienna Biopharmaceuticals (NASDAQ SNNA) News Headlines

Source:
DateHeadline
Sienna Biopharmaceuticals (SNNA) Receives Average Recommendation of "Hold" from AnalystsSienna Biopharmaceuticals (SNNA) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 20 at 11:33 AM
Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breaker at the International Investigative Dermatology CongressSienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breaker at the International Investigative Dermatology Congress
www.streetinsider.com - May 16 at 9:54 AM
Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breaker at the International Investigative Dermatology CongressSienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breaker at the International Investigative Dermatology Congress
finance.yahoo.com - May 16 at 9:54 AM
Sienna Biopharmaceuticals (SNNA) Releases Quarterly  Earnings Results, Misses Expectations By $0.15 EPSSienna Biopharmaceuticals (SNNA) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPS
www.americanbankingnews.com - May 15 at 7:34 AM
Sienna Biopharmaceuticals Reports First Quarter 2018 Financial ResultsSienna Biopharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 14 at 10:34 AM
Sienna Biopharmaceuticals to Present at BAML Health Care ConferenceSienna Biopharmaceuticals to Present at BAML Health Care Conference
finance.yahoo.com - May 11 at 10:40 AM
Sienna Biopharmaceuticals (SNNA) Lifted to Hold at ValuEngineSienna Biopharmaceuticals (SNNA) Lifted to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 6:06 PM
Insider Selling: Sienna Biopharmaceuticals (SNNA) Insider Sells 975 Shares of StockInsider Selling: Sienna Biopharmaceuticals (SNNA) Insider Sells 975 Shares of Stock
www.americanbankingnews.com - April 25 at 10:16 PM
Sienna Biopharmaceuticals (SNNA) Given Average Rating of "Hold" by BrokeragesSienna Biopharmaceuticals (SNNA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 25 at 11:28 AM
Insider Selling: Sienna Biopharmaceuticals Inc (SNNA) Insider Sells 18,011 Shares of StockInsider Selling: Sienna Biopharmaceuticals Inc (SNNA) Insider Sells 18,011 Shares of Stock
www.americanbankingnews.com - April 19 at 7:34 PM
Sienna Biopharmaceuticals Inc (SNNA) Insider Todd Harris Sells 8,210 SharesSienna Biopharmaceuticals Inc (SNNA) Insider Todd Harris Sells 8,210 Shares
www.americanbankingnews.com - April 9 at 10:26 PM
Sienna Biopharmaceuticals (SNNA) Lowered to Sell at Zacks Investment ResearchSienna Biopharmaceuticals (SNNA) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 31 at 1:08 PM
Sienna Biopharmaceuticals Inc (SNNA) Receives Average Recommendation of "Hold" from AnalystsSienna Biopharmaceuticals Inc (SNNA) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 31 at 11:32 AM
Robert J. More Sells 24,429 Shares of Sienna Biopharmaceuticals Inc (SNNA) StockRobert J. More Sells 24,429 Shares of Sienna Biopharmaceuticals Inc (SNNA) Stock
www.americanbankingnews.com - March 29 at 10:28 PM
Sienna Biopharmaceuticals (SNNA) Announces John W. Smither as Chief Financial OfficerSienna Biopharmaceuticals (SNNA) Announces John W. Smither as Chief Financial Officer
www.streetinsider.com - March 22 at 9:54 AM
Sienna Biopharmaceuticals Appoints John W. Smither as Chief Financial OfficerSienna Biopharmaceuticals Appoints John W. Smither as Chief Financial Officer
finance.yahoo.com - March 22 at 9:54 AM
Sienna Biopharmaceuticals Appoints Caroline Van Hove as Chief Commercial OfficerSienna Biopharmaceuticals Appoints Caroline Van Hove as Chief Commercial Officer
finance.yahoo.com - March 22 at 9:54 AM
Insider Selling: Sienna Biopharmaceuticals Inc (SNNA) Insider Sells 5,876 Shares of StockInsider Selling: Sienna Biopharmaceuticals Inc (SNNA) Insider Sells 5,876 Shares of Stock
www.americanbankingnews.com - March 20 at 8:10 PM
Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsSienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 15 at 9:35 AM
Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic DermatitisSienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
finance.yahoo.com - March 12 at 10:36 AM
Insider Selling: Sienna Biopharmaceuticals Inc (SNNA) Insider Sells 20,672 Shares of StockInsider Selling: Sienna Biopharmaceuticals Inc (SNNA) Insider Sells 20,672 Shares of Stock
www.americanbankingnews.com - March 9 at 9:28 PM
Sienna Biopharmaceuticals to Present at Cowen and Company Health Care ConferenceSienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference
finance.yahoo.com - March 6 at 9:31 AM
Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125
finance.yahoo.com - February 14 at 4:40 PM
Sienna Biopharmaceuticals (SNNA) Lifted to "Sell" at ValuEngineSienna Biopharmaceuticals (SNNA) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 1:16 PM
Sienna Biopharmaceuticals Incs (SNNA) Lock-Up Period To End  on January 23rdSienna Biopharmaceuticals Inc's (SNNA) Lock-Up Period To End on January 23rd
www.americanbankingnews.com - January 16 at 1:14 AM
Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare ConferenceSienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
finance.yahoo.com - December 11 at 9:37 AM
The 10 Best New Stocks of 2017The 10 Best New Stocks of 2017
finance.yahoo.com - December 6 at 9:05 AM
Sienna Biopharmaceuticals (SNNA) Earns Neutral Rating from Analysts at GuggenheimSienna Biopharmaceuticals (SNNA) Earns Neutral Rating from Analysts at Guggenheim
www.americanbankingnews.com - December 5 at 8:48 PM
Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial ResultsSienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 1:45 PM
Sienna Biopharmaceuticals (SNNA) Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120Sienna Biopharmaceuticals (SNNA) Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
www.streetinsider.com - October 25 at 10:53 AM
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
finance.yahoo.com - October 24 at 10:12 AM
SIENNA BIOPHARM (SNNA) Director Dennis M. Fenton Purchases 1,250 SharesSIENNA BIOPHARM (SNNA) Director Dennis M. Fenton Purchases 1,250 Shares
www.americanbankingnews.com - September 19 at 4:28 PM
SIENNA BIOPHARM (SNNA) Releases Quarterly  Earnings Results, Misses Expectations By $5.82 EPSSIENNA BIOPHARM (SNNA) Releases Quarterly Earnings Results, Misses Expectations By $5.82 EPS
www.americanbankingnews.com - September 8 at 9:29 AM
Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial ResultsSienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results
finance.yahoo.com - September 7 at 9:14 AM
Sienna Biopharms (SNNA) Quiet Period Will End  on September 5thSienna Biopharm's (SNNA) Quiet Period Will End on September 5th
www.americanbankingnews.com - September 2 at 1:22 AM
Sienna Biopharm (SNNA) Coverage Initiated at Cowen and CompanySienna Biopharm (SNNA) Coverage Initiated at Cowen and Company
www.americanbankingnews.com - August 21 at 8:52 AM
Sienna Biopharm (SNNA) Receives New Coverage from Analysts at J P Morgan Chase & CoSienna Biopharm (SNNA) Receives New Coverage from Analysts at J P Morgan Chase & Co
www.americanbankingnews.com - August 21 at 8:36 AM
Sienna Biopharm (SNNA) Now Covered by Analysts at BMO Capital MarketsSienna Biopharm (SNNA) Now Covered by Analysts at BMO Capital Markets
www.americanbankingnews.com - August 21 at 8:08 AM
Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesSienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - August 2 at 3:26 PM
Sienna Biopharmaceuticals Inc (SNNA) General Counsel Buys $225,000.00 in StockSienna Biopharmaceuticals Inc (SNNA) General Counsel Buys $225,000.00 in Stock
www.americanbankingnews.com - August 1 at 10:14 PM
Paul F. Lizzul Buys 10,000 Shares of Sienna Biopharmaceuticals Inc (SNNA) StockPaul F. Lizzul Buys 10,000 Shares of Sienna Biopharmaceuticals Inc (SNNA) Stock
www.americanbankingnews.com - August 1 at 7:50 PM
Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) CFO Acquires $105,000.00 in StockSienna Biopharmaceuticals Inc (NASDAQ:SNNA) CFO Acquires $105,000.00 in Stock
www.americanbankingnews.com - August 1 at 7:50 PM
Sienna Biopharmaceuticals Inc (SNNA) Director Keith R. Leonard Acquires 16,700 SharesSienna Biopharmaceuticals Inc (SNNA) Director Keith R. Leonard Acquires 16,700 Shares
www.americanbankingnews.com - August 1 at 7:48 PM
Sienna Biopharmaceuticals Prices IPO at $14.00-$16.00 Per Share (NASDAQ:SNNA)Sienna Biopharmaceuticals Prices IPO at $14.00-$16.00 Per Share (NASDAQ:SNNA)
www.americanbankingnews.com - July 19 at 10:58 AM

SEC Filings

Sienna Biopharmaceuticals (NASDAQ:SNNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sienna Biopharmaceuticals (NASDAQ:SNNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sienna Biopharmaceuticals (NASDAQ SNNA) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.